Focus: Vanda is a public specialty pharma company focused on neurology and sleep disorders, headquartered in Washington, DC. They commercialize three marketed products generating ~$193M in annual revenue with a 40% R&D intensity.
Profile data last refreshed 19h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Vanda Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Help build intelligence for Vanda Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Vanda Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship revenue driver (46% of total) treating rare circadian rhythm disorders; strong patent protection through 2041 but faces generic competition from ANDA filers.
Second-largest revenue contributor (48% combined with HETLIOZ); atypical antipsychotic with longer patent tail than HETLIOZ but earlier LOE exposure (2031).
S1P receptor modulator with lower commercial penetration; represents diversification into autoimmune but contributes <5% of revenue.
2 discontinued, 4 duplicate formulations not shown
Vanda Pharmaceuticals (NASDAQ: VNDA) executive details stock, options and RSUs - Stock Titan
Vanda Pharmaceuticals (NASDAQ: VNDA) executive details stock, options and RSUs Stock Titan
Vanda Pharmaceuticals opposes FDA drug review timeline proposal By Investing.com - Investing.com Nigeria
Vanda Pharmaceuticals opposes FDA drug review timeline proposal By Investing.com Investing.com Nigeria
Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines – Company Announcement - FT.com - Financial Times
Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines – Company Announcement - FT.com Financial Times
Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines - PR Newswire
Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines PR Newswire
Vanda initiates study of motion sickness drug Nereus in GLP-1 users - Fierce Pharma
Vanda initiates study of motion sickness drug Nereus in GLP-1 users Fierce Pharma
Vanda Pharmaceuticals opposes FDA drug review timeline proposal - Investing.com
Vanda Pharmaceuticals opposes FDA drug review timeline proposal Investing.com
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Based on last 3 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo